Crystallographic Identification of Lipid as an Integral Component of the Epitope of HIV Broadly Neutralizing Antibody 4E10

Immunity

Volumn 44, Issue 1, 2016, Pages 21-31

  Irimia, Adriana ^a,b   Sarkar, Anita ^a,b   Stanfield, Robyn L ^a,b   Wilson, Ian A ^a,b  

^a Department of Integrative Structural and Computational Biology   (United States)

^b Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN; EPITOPE; GLYCEROPHOSPHATE; LIPID; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY 4E10; PHOSPHATIDIC ACID; PHOSPHATIDYLGLYCEROL; UNCLASSIFIED DRUG; 4E10 MONOCLONAL ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MEMBRANE LIPID; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; ANTIBODY COMBINING SITE; CELL LINE; CHEMISTRY; HUMAN; IMMUNOLOGY; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BINDING SITES, ANTIBODY; CELL LINE; CRYSTALLOGRAPHY, X-RAY; EPITOPES, B-LYMPHOCYTE; HIV ANTIBODIES; HUMANS; MEMBRANE LIPIDS; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 84958847963     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2015.12.001     Document Type: Article

References (56)

1. Adams P.D., Afonine P.V., Bunkóczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.W., Kapral G.J., Grosse-Kunstleve R.W., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:213-221.
2. Alam S.M., McAdams M., Boren D., Rak M., Scearce R.M., Gao F., Camacho Z.T., Gewirth D., Kelsoe G., Chen P., Haynes B.F. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 2007, 178:4424-4435.
3. Alam S.M., Morelli M., Dennison S.M., Liao H.X., Zhang R., Xia S.M., Rits-Volloch S., Sun L., Harrison S.C., Haynes B.F., Chen B. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 2009, 106:20234-20239.
4. Aloia R.C., Tian H., Jensen F.C. Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc. Natl. Acad. Sci. USA 1993, 90:5181-5185.
5. Asherson R.A., Cervera R. Antiphospholipid antibodies and infections. Ann. Rheum. Dis. 2003, 62:388-393.
6. Brooks B.R., Brooks C.L., Mackerell A.D., Nilsson L., Petrella R.J., Roux B., Won Y., Archontis G., Bartels C., Boresch S., et al. CHARMM: the biomolecular simulation program. J. Comput. Chem. 2009, 30:1545-1614.
7. Brunel F.M., Zwick M.B., Cardoso R.M., Nelson J.D., Wilson I.A., Burton D.R., Dawson P.E. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J. Virol. 2006, 80:1680-1687.
8. Buzon V., Natrajan G., Schibli D., Campelo F., Kozlov M.M., Weissenhorn W. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010, 6:e1000880.
9. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., Burton D.R., Wilson I.A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22:163-173.
10. Cardoso R.M., Brunel F.M., Ferguson S., Zwick M., Burton D.R., Dawson P.E., Wilson I.A. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J. Mol. Biol. 2007, 365:1533-1544.
11. Cazzolli R., Shemon A.N., Fang M.Q., Hughes W.E. Phospholipid signalling through phospholipase D and phosphatidic acid. IUBMB Life 2006, 58:457-461.
12. Chen Y., Zhang J., Hwang K.K., Bouton-Verville H., Xia S.M., Newman A., Ouyang Y.B., Haynes B.F., Verkoczy L. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J. Immunol. 2013, 191:1260-1275.
13. Chen J., Frey G., Peng H., Rits-Volloch S., Garrity J., Seaman M.S., Chen B. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J. Virol. 2014, 88:1249-1258.
14. Chien M.P., Jiang S., Chang D.K. The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusion. FASEB J. 2008, 22:1179-1192.
15. Chun T.W., Fauci A.S. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012, 26:1261-1268.
16. Dennison S.M., Sutherland L.L., Jaeger F.H., Anasti K.M., Parks R., Stewart S., Bowman C., Xia S.M., Zhang R., Shen X., et al. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS ONE 2011, 6:e27824.
17. Doyle-Cooper C., Hudson K.E., Cooper A.B., Ota T., Skog P., Dawson P.E., Zwick M.B., Schief W.R., Burton D.R., Nemazee D. Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J. Immunol. 2013, 191:3186-3191.
18. Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:486-501.
19. Finton K.A., Larimore K., Larman H.B., Friend D., Correnti C., Rupert P.B., Elledge S.J., Greenberg P.D., Strong R.K. Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog. 2013, 9:e1003639.
20. Frey G., Peng H., Rits-Volloch S., Morelli M., Cheng Y., Chen B. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 2008, 105:3739-3744.
21. Harrison S.C. Viral membrane fusion. Nat. Struct. Mol. Biol. 2008, 15:690-698.
22. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
23. Huang J., Ofek G., Laub L., Louder M.K., Doria-Rose N.A., Longo N.S., Imamichi H., Bailer R.T., Chakrabarti B., Sharma S.K., et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491:406-412.
24. Ingale S., Gach J.S., Zwick M.B., Dawson P.E. Synthesis and analysis of the membrane proximal external region epitopes of HIV-1. J. Pept. Sci. 2010, 16:716-722.
25. Julien J.P., Bryson S., Nieva J.L., Pai E.F. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J. Mol. Biol. 2008, 384:377-392.
26. Julien J.P., Cupo A., Sok D., Stanfield R.L., Lyumkis D., Deller M.C., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
27. Kabsch W. XDS. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:125-132.
28. Lorizate M., Sachsenheimer T., Glass B., Habermann A., Gerl M.J., Kräusslich H.G., Brügger B. Comparative lipidomics analysis of HIV-1 particles and their producer cell membrane in different cell lines. Cell. Microbiol. 2013, 15:292-304.
29. Lyumkis D., Julien J.P., de Val N., Cupo A., Potter C.S., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., Carragher B., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490.
30. Matyas G.R., Beck Z., Karasavvas N., Alving C.R. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim. Biophys. Acta 2009, 1788:660-665.
31. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Cryst. 2007, 40:658-674.
32. Mehandru S., Vcelar B., Wrin T., Stiegler G., Joos B., Mohri H., Boden D., Galovich J., Tenner-Racz K., Racz P., et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J. Virol. 2007, 81:11016-11031.
33. Montero M., van Houten N.E., Wang X., Scott J.K. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 2008, 72:54-84.
34. Morita S.Y., Terada T. Enzymatic measurement of phosphatidylglycerol and cardiolipin in cultured cells and mitochondria. Sci. Rep. 2015, 5:11737.
35. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 2004, 78:10724-10737.
36. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
37. Pancera M., Zhou T., Druz A., Georgiev I.S., Soto C., Gorman J., Huang J., Acharya P., Chuang G.Y., Ofek G., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014, 514:455-461.
38. Paruch S., Heinis M., Lemay J., Hoeffel G., Marañón C., Hosmalin A., Périanin A. CCR5 signaling through phospholipase D involves p44/42 MAP-kinases and promotes HIV-1 LTR-directed gene expression. FASEB J. 2007, 21:4038-4046.
39. Rathinakumar R., Dutta M., Zhu P., Johnson W.E., Roux K.H. Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions. J. Virol. 2012, 86:1820-1831.
40. Rout A.K., Strub M.P., Piszczek G., Tjandra N. Structure of transmembrane domain of lysosome-associated membrane protein type 2a (LAMP-2A) reveals key features for substrate specificity in chaperone-mediated autophagy. J. Biol. Chem. 2014, 289:35111-35123.
41. Salzwedel K., West J.T., Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 1999, 73:2469-2480.
42. Scherer E.M., Zwick M.B., Teyton L., Burton D.R. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 2007, 21:2131-2139.
43. Scherer E.M., Leaman D.P., Zwick M.B., McMichael A.J., Burton D.R. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc. Natl. Acad. Sci. USA 2010, 107:1529-1534.
44. Sène D., Piette J.C., Cacoub P. [Antiphospholipid antibodies, antiphospholipid syndrome and viral infections]. Rev. Med. Interne 2009, 30:135-141.
45. Serrano S., Araujo A., Apellániz B., Bryson S., Carravilla P., de la Arada I., Huarte N., Rujas E., Pai E.F., Arrondo J.L., et al. Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design. J. Biol. Chem. 2014, 289:6565-6580.
46. Singh H., Henry K.A., Wu S.S., Chruscinski A., Utz P.J., Scott J.K. Reactivity profiles of broadly neutralizing anti-HIV-1 antibodies are distinct from those of pathogenic autoantibodies. AIDS 2011, 25:1247-1257.
47. Sun Z.Y., Oh K.J., Kim M., Yu J., Brusic V., Song L., Qiao Z., Wang J.H., Wagner G., Reinherz E.L. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008, 28:52-63.
48. Sundquist W.I., Kräusslich H.G. HIV-1 assembly, budding, and maturation. Cold Spring Harb. Perspect. Med. 2012, 2:a006924.
49. The PyMOL molecular graphics system, version 1.3, Schrödinger, LLC.
50. Tran E.E., Borgnia M.J., Kuybeda O., Schauder D.M., Bartesaghi A., Frank G.A., Sapiro G., Milne J.L., Subramaniam S. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 2012, 8:e1002797.
51. van Meer G., Voelker D.R., Feigenson G.W. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 2008, 9:112-124.
52. Vcelar B., Stiegler G., Wolf H.M., Muntean W., Leschnik B., Mehandru S., Markowitz M., Armbruster C., Kunert R., Eibl M.M., Katinger H. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 2007, 21:2161-2170.
53. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., Wang S.K., Ramos A., Chan-Hui P.Y., Moyle M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470. Protocol G Principal Investigators.
54. Yang G., Holl T.M., Liu Y., Li Y., Lu X., Nicely N.I., Kepler T.B., Alam S.M., Liao H.X., Cain D.W., et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J. Exp. Med. 2013, 210:241-256.
55. Zwick M.B. The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring. AIDS 2005, 19:1725-1737.
56. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75:10892-10905.